⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11094656 | 0.88 | — | — | |
| SCHEMBL17062485 | 0.88 | — | — | |
| SCHEMBL754743 | 0.85 | NPC1 (0.40) | — | |
| SCHEMBL2076964 | 0.81 | SUCNR1 (0.33) | — | |
| SCHEMBL2838225 | 0.71 | — | — | |
| SCHEMBL21315004 | 0.71 | — | — | |
| SCHEMBL821436 | 0.69 | — | — | |
| SCHEMBL892513 | 0.69 | TSHR (0.44) | — | |
| SCHEMBL6678007 | 0.69 | — | — | |
| SCHEMBL1398495 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | claimed |
| WO-2022108995-A1 | COMPOSITIONS AND METHODS FOR BLOCKING NEUROPILIN RECEPTOR 1 FOR THE TREATMENT OF PAIN AND PREVENTION OF VIRAL ENTRY | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-05-27 | — | — | WO | claimed |
| US-20210395258-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | claimed |
| US-11078204-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-08-03 | — | — | US | claimed |
| WO-2020102198-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | claimed |
| US-20200148689-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | claimed |
| US-20200062753-A1 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2020-02-27 | — | — | US | claimed |
| US-10428069-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-10-01 | — | — | US | claimed |
| CN-109232613-A | For treating and preventing the condensed heteroaryl dihydro-pyrimidin of hepatitis b virus infected new 6- | 豪夫迈·罗氏有限公司 | 2019-01-18 | — | — | CN | claimed |
| EP-3114128-B1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-01-02 | — | — | EP | claimed |
| US-20180370969-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | claimed |
| CN-106061978-B | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infections | 豪夫迈·罗氏有限公司 | 2018-10-23 | — | — | CN | claimed |
| US-10081627-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-09-25 | — | — | US | claimed |
| EP-3114128-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-01-11 | — | — | EP | claimed |
| CN-106061978-A | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infections | 豪夫迈·罗氏有限公司 | 2016-10-26 | — | — | CN | claimed |
| US-20160083383-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | claimed |
| US-9233978-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-01-12 | — | — | US | claimed |
| WO-2015132276-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-11 | — | — | WO | claimed |
| US-20150252057-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | claimed |
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | disclosed |
| US-11937603-B2 | Maleimide derivatives having herbicidal activity, agronomic compositions of the maleimide derivatives, and uses thereof | GOWAN COMPANY, LLC (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240002361-A1 | COMPOSITIONS AND METHODS FOR BLOCKING NEUROPILIN RECEPTOR 1 FOR THE TREATMENT OF PAIN AND PREVENTION OF VIRAL ENTRY | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2024-01-04 | — | — | US | disclosed |
| US-20230046892-A1 | SUBSTITUTED THIOPHENE CARBOXAMIDES, THIOPHENE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-16 | — | — | US | disclosed |
| WO-2022108995-A1 | COMPOSITIONS AND METHODS FOR BLOCKING NEUROPILIN RECEPTOR 1 FOR THE TREATMENT OF PAIN AND PREVENTION OF VIRAL ENTRY | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20210395258-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | disclosed |
| US-11078204-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2020255017-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| EP-3749661-A1 | MALEIMIDE DERIVATIVES HAVING A HERBICIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND USE THEREOF | ISAGRO S.p.A. (IT) | 2020-12-16 | — | — | EP | disclosed |
| US-20200375186-A1 | MALEIMIDE DERIVATIVES HAVING HERBICIDAL ACTIVITY, AGRONOMIC COMPOSITIONS OF THE MALEIMIDE DERIVATIVES, AND USES THEREOF | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2020-12-03 | — | — | US | disclosed |
| CN-111788190-A | Maleimide derivative having herbicidal activity, agricultural composition containing the same, and use thereof | 伊萨格罗股份公司 | 2020-10-16 | — | — | CN | disclosed |
| WO-2020102198-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148689-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-20200062753-A1 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-10428069-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2019155400-A1 | MALEIMIDE DERIVATIVES HAVING A HERBICIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND USE THEREOF | ISAGRO S.P.A. (IT) | 2019-08-15 | — | — | WO | disclosed |
| CN-105814049-B | Fused tricyclic imdazole derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2019-03-12 | — | — | CN | disclosed |
| CN-109232613-A | For treating and preventing the condensed heteroaryl dihydro-pyrimidin of hepatitis b virus infected new 6- | 豪夫迈·罗氏有限公司 | 2019-01-18 | — | — | CN | disclosed |
| EP-3114128-B1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-01-02 | — | — | EP | disclosed |
| US-20180370969-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| CN-106061978-B | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infections | 豪夫迈·罗氏有限公司 | 2018-10-23 | — | — | CN | disclosed |
| US-10081627-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-09-25 | — | — | US | disclosed |
| CN-105814048-B | Fused tricyclic benzimidizole derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107787319-A | Indazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2018-03-09 | — | — | CN | disclosed |
| CN-105814052-B | Imidazopyridine derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-01-12 | — | — | CN | disclosed |
| CN-107513073-A | For treating and preventing the heteroaryl dihydro-pyrimidin of hepatitis b virus infected 6 new fusions | 豪夫迈·罗氏有限公司 | 2017-12-26 | — | — | CN | disclosed |
| EP-3114128-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-01-11 | — | — | EP | disclosed |
| EP-3103792-A1 | INTERMEDIATES FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE | Clovis Oncology Italy S.r.l. (IT) | 2016-12-14 | — | — | EP | disclosed |
| CN-106061978-A | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infections | 豪夫迈·罗氏有限公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-105814049-A | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814048-A | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814052-A | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| EP-2641897-B1 | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | CLOVIS ONCOLOGY ITALY S R L (IT) | 2016-07-13 | — | — | EP | disclosed |
| US-9340508-B2 | Process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2016-05-17 | — | — | US | disclosed |
| US-20160083383-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-9233978-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-01-12 | — | — | US | disclosed |
| WO-2015132276-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-11 | — | — | WO | disclosed |
| US-20150252057-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150191429-A1 | Process for the Preparation of 6-(7-((1-Aminocyclopropyl)Methoxy)-6-Methoxyquinolin-4-Yloxy)-N-Methyl-1-Naphthamide and Synthetic Intermediates Thereof | EOS ETHICAL ONCOLOGY SCIENCE, S.P.A., ABBREVIATED FORM EOS S.P.A. (IT) | 2015-07-09 | — | — | US | disclosed |
| US-9012645-B2 | Process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| US-20140114075-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S.P.A. IN ABBREVIATED FORM EOS S.P.A. (IT) | 2014-04-24 | — | — | US | disclosed |
| US-8642767-B2 | Process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | EOS Ethical Oncology S.p.A. Abbreviated Form EOS S.p.A. (IT) | 2014-02-04 | — | — | US | disclosed |
| EP-2641897-A2 | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | EOS Ethical Oncology Science S.p.A. In Abbreviated From EOS S.p.A. (IT) | 2013-09-25 | — | — | EP | disclosed |
| EP-2408739-B1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE SPA IN ABBREVIATED FORM EOS SPA (IT) | 2013-08-14 | — | — | EP | disclosed |
| EP-2408739-A1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS Ethical Oncology Science S.p.A. In Abbreviated From EOS S.p.A. (IT) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010415-A1 | PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | CLOVIS ONCOLOGY ITALY S.R.L. (IT) | 2012-01-12 | — | — | US | disclosed |
| WO-2010105761-A1 | A PROCESS FOR THE PREPARATION OF 6-(7-((1-AMINOCYCLOPROPYL)METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1-NAPHTHAMIDE AND SYNTHETIC INTERMEDIATES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S.P.A. IN ABBREVIATED FORM EOS S.P.A. (IT) | 2010-09-23 | — | — | WO | disclosed |
| EP-0945445-B9 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |